23 November 2020[1]
EMA/PRAC/570590/2020
Pharmacovigilance Risk Assessment Committee (PRAC)

New product information wording – Extracts from PRAC recommendations on signals

Adopted at the 26-29 October 2020 PRAC

The product information wording in this document is extracted from the document entitled 'PRAC recommendations on signals' which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found ***here*** (in English only).

New text to be added to the product information is underlined. Current text to be deleted is ~~struck through~~.

1. Ceftriaxone – Encephalopathy (EPITT no 19492)

Summary of product characteristics

4.4. Special warnings and precautions for use

Encephalopathy

Encephalopathy has been reported with the use of ceftriaxone (see section 4.8), particularly in elderly patients with severe renal impairment (see section 4.2) or central nervous system disorders. If ceftriaxone-associated encephalopathy is suspected (e.g. decreased level of consciousness, altered mental state, myoclonus, convulsions), discontinuation of ceftriaxone should be considered.

4.8. Undesirable effects

Nervous system disorders

Frequency 'rare': Encephalopathy

Package leaflet

2. Warnings and precautions

[1] Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Talk to your doctor or pharmacist before taking your medicine if:

[…]

- You have liver or kidney problems (see section 4)

4. Possible side effects

Treatment with ceftriaxone, particularly in elderly patients with serious kidney or nervous system problems may rarely cause decreased consciousness, abnormal movements, agitation and convulsions.

2. Dabrafenib; trametinib – Sarcoidosis (EPITT no 19574)

Tafinlar (dabrafenib) - Summary of product characteristics

4.4. Special warnings and precautions for use

Sarcoidosis

Cases of sarcoidosis have been reported in patients treated with dabrafenib in combination with trametinib, mostly involving the skin, lung, eye and lymph nodes. In the majority of the cases, treatment with dabrafenib and trametinib was maintained. In case of a diagnosis of sarcoidosis, relevant treatment should be considered. It is important not to misinterpret sarcoidosis as disease progression.

4.8. Undesirable effects

Tabulated list of adverse reactions – Table 4

Immune system disorders

Uncommon: Sarcoidosis

Tafinlar (dabrafenib) - Package leaflet

2. What you need to know before you take Tafinlar

Conditions you may need to look out for

An inflammatory disease mainly affecting the skin, lung, eyes and lymph nodes (sarcoidosis). Common symptoms of sarcoidosis may include coughing, shortness of breath, swollen lymph nodes, visual disturbances, fever, fatigue, pain and swelling in the joints and tender bumps on your skin. Tell your doctor if you get any of these symptoms.

4. Possible side effects

Possible side effects when Tafinlar and trametinib are taken together

Uncommon side effects (may affect up to 1 in every 100 people):

- Inflammatory disease mainly affecting the skin, lung, eyes and lymph nodes (sarcoidosis)

Mekinist (trametinib) - Summary of product characteristics

4.4. Special warnings and precautions for use

Sarcoidosis

Cases of sarcoidosis have been reported in patients treated with trametinib in combination with dabrafenib, mostly involving the skin, lung, eye and lymph nodes. In the majority of the cases, treatment with trametinib and dabrafenib was maintained. In case of a diagnosis of sarcoidosis, relevant treatment should be considered. It is important not to misinterpret sarcoidosis as disease progression.

4.8. Undesirable effects

Tabulated list of adverse reactions – Table 5

Immune system disorders

Uncommon: Sarcoidosis

Mekinist (trametinib) - Package leaflet

2. What you need to know before you take Mekinist

Conditions you need to look out for

An inflammatory disease mainly affecting the skin, lung, eyes and lymph nodes (sarcoidosis). Common symptoms of sarcoidosis may include coughing, shortness of breath, swollen lymph nodes, visual disturbances, fever, fatigue, pain and swelling in the joints and tender bumps on your skin. Tell your doctor if you get any of these symptoms.

4. Possible side effects

Side effects when Mekinist and dabrafenib are taken together

Uncommon side effects (may affect up to 1 in 100 people):

- Inflammatory disease mainly affecting the skin, lung, eyes and lymph nodes (sarcoidosis)

3. Ibrutinib – Hepatitis E (EPITT no 19569)

Summary of product characteristics

4.4. Special warnings and precautions for use

Infections

[…] Patients should be monitored for fever, abnormal liver function tests, neutropenia and infections and appropriate anti-infective therapy should be instituted as indicated. […]

Cases of hepatitis E, which may be chronic, have occurred in patients treated with IMBRUVICA.

Package leaflet

2. What you need to know before you take IMBRUVICA

Warnings and precautions

You may experience viral, bacterial, or fungal infections during treatment with IMBRUVICA. Contact your doctor if you have fever, chills, weakness, confusion, body aches, cold or flu symptoms, feel tired or feel short of breath, yellowing of the skin or eyes (jaundice). These could be signs of an infection.

4. Lamotrigine – Photosensitivity (EPITT no 19548)

Summary of product characteristics

4.4. Special warnings and precautions for use

Skin rash *(new text to be added at the end of the paragraph)*

[…]

There have also been reports of photosensitivity reactions associated with lamotrigine use (see section 4.8). In several cases, the reaction occurred with a high dose (400mg or more), upon dose escalation or rapid up-titration. If lamotrigine-associated photosensitivity is suspected in a patient showing signs of photosensitivity (such as an exaggerated sunburn), treatment discontinuation should be considered. If continued treatment with lamotrigine is considered clinically justified, the patient should be advised to avoid exposure to sunlight and artificial UV light and take protective measures (e.g. use of protective clothing and sunscreens).

4.8. Undesirable effects

System Organ Class	Adverse events	Frequency
Skin and subcutaneous tissue disorders	[…] photosensitivity reaction	Uncommon

Package leaflet

2. What you need to know before you take [product name]

[…]

Take special care with [product name]

Talk to your doctor or pharmacist before taking [product name]:

- […]
- if you have ever developed a rash after taking lamotrigine or other medicines for bipolar disorder or epilepsy; or if you experience a rash or sunburn after taking lamotrigine and having been exposed to sun or artificial light (e.g. solarium). Your doctor will check your treatment and may advise you to avoid sunlight or protect yourself against the sun (e.g. use of a sunscreen and/or to wear protective clothing).

4. Possible side effects

Uncommon side effects

These may affect up to 1 in 100 people:

- skin rash or sunburn after exposure to sun or artificial light (photosensitivity)